The USD 1,000 Fee and ISO 9001, Not ISO 13485

1. Key takeaways

The two most frequently retold figures are written clearly in the official original: USD 1,000 is the company registration fee, not a product registration fee charged per product or per model, and the official wording for the quality assurance system certificate is ISO 9001, 9002 or equivalent, with ISO 13485 nowhere in the original text. Both points come from the Drug Registration Regulations published by the Registration Department of the Technical Affairs Directorate of the Iraqi Ministry of Health — a document with no document number, no publication date and only secondary reproduction, which can be used only as a statement of fact. From this follows a judgement that is often overlooked: meeting the minimum statutory requirements and meeting commercial requirements are two different thresholds in Iraq, and companies should prepare for the latter.

• The official clause reads in full: Company registration fee $ 1000 — the word company defines the entity on which the fee falls.
• The official clause on the system certificate reads: Quality assurance certificate such as ISO 9001, 9002 or equivalent — ISO 13485 does not appear.
• For contrast, pharmaceuticals are charged per product at USD 165 with re-registration at USD 100, a fee logic separate from the per-company device fee.
• Meeting the minimum legal requirement and meeting the commercial requirement are distinct thresholds; ISO 13485 serves the commercial one.

2. Legal basis

The table below lists the sources cited in this article together with their document numbers, publication dates and the provisions relied upon.

Source grading: the Drug Registration Regulations is graded secondary and must not be cited as a legal provision (hosted at https://pharmexcil.com/uploadfile/ufiles/380351111_drug_regpdf.pdf; the official original was not obtained). The Country Profile 2020 is graded primary, indirectly verified (the source site was blocked and the content was obtained through indexed snippets).

Excerpts of the original provisions:

• Section D item 6: «Company registration fee $ 1000.» — the sentence is only these words, and company qualifies the entity bearing the fee.
• Section D item 2: «Quality assurance certificate such as ISO 9001, 9002 or equivalent.» — a quality assurance system certificate, for example ISO 9001, 9002 or equivalent.
• Section E item 26 (for contrast): a registration fee of USD 165 per product, and IQD 2,500 for domestic products; Section E item 27: a re-registration fee of USD 100. Charging pharmaceuticals per product and devices per company are two separate logics.
• Country Profile 2020 Section 6.6: «Any pharmaceutical companies have one or more well-known certificate(s) such as from EMA/FDA, will be exempted from the inspection visit before company registration» — companies holding well-known certificates such as EMA or FDA are exempt from the inspection visit before company registration.

3. Expert insights

Insight 1 | USD 1,000 determines the cost model of the entire project. If it were a product fee, budgets would grow linearly with the number of SKUs; as a company fee, once paid, in theory all subsequent imports of that company’s products amortize the cost. What actually consumes the budget is not the official fee but embassy legalization, translation, travel and in-person follow-up. GRZAN always separates officially sourced amounts from unofficial expenditure in quotations and lists each item in the contract.

Insight 2 | Cross-border comparison: the prevailing system standard in the device sector is ISO 13485. China’s Good Manufacturing Practice for medical devices, the QMS required by Article 10 of the EU MDR, and the FDA QMSR in the United States, which incorporates ISO 13485 into 21 CFR 820, all point to ISO 13485. The Iraqi official text reads ISO 9001 or 9002 — the latter is a 1990s edition long since merged into ISO 9001:2000 and withdrawn. This wording is itself a key clue to the age of the text: it was most likely drafted around the transition between those editions and not updated since.

Insight 3 | Debunking: presenting ISO 13485 as legally mandatory in Iraq mistakes a commercial requirement for a regulatory one. The official document says or equivalent, an open catch-all showing that the Registration Department cares about proof of a system rather than any specific standard number. Conversely, a company claiming publicly that Iraqi law requires ISO 13485 sees the credibility of all its documents questioned once checked. GRZAN’s formulation is always that the official text requires a quality assurance certificate citing ISO 9001, 9002 or equivalent, and that ISO 13485 in practice serves the commercial purpose.

Insight 4 | Why companies should nevertheless choose ISO 13485. Three reasons. First, purchasers recognize it: tender documents and multi-tier agent screening routinely write ISO 13485 into qualification clauses, a de facto threshold. Second, it is reusable: one ISO 13485 certificate can also support the QMS elements of EU CE marking under MDR (EU) 2017/745 Article 10, MDSAP member jurisdictions and the US QMSR, at low marginal cost. Third, it eases proof: some purchasers treat ISO 13485 differently from ISO 9001 when reviewing certificates one by one.

Insight 5 | The line between the minimum requirement and the commercial requirement must be written into internal rules. Iraq is a market with absent statutory text and dense administrative notices: a window officer may accept the six items today and demand an extra CFS tomorrow. GRZAN sets the compliance baseline by the official text and the delivery standard by the strictest common commercial practice — prepare the dossier for the worst case, while negotiating externally from the official list, so as not to raise the bar and have it locked in against oneself.

4. Practical recommendations

• State clearly in the quotation that the only officially sourced fee is the company registration fee of USD 1,000, classify everything else as practical expenditure, and note that no official provision was found for other amounts, which are subject to official notice at acceptance.
• Prepare the system certificate as ISO 13485:2016 with an English version, and confirm the accreditation mark of the certification body, such as CNAS, UKAS or ANAB, so it is recognized in tender reviews.
• Practical estimate: obtain ISO 13485:2016 as well, since its QMS output can be reused across several Gulf and Southeast Asian markets (no official provision found).
• Keep written records in communications with the Iraqi counterpart that ISO 13485, exceeding the ISO 9001 or 9002 requirement, has been submitted, as evidence of diligence should the standard be raised later.
• Watch whether the rates shown in Section E items 26 and 27, USD 165 for pharmaceuticals and USD 100 for re-registration, are adjusted by later instructions; devices are not covered, but fee adjustments often occur in the same period and serve as an intelligence signal.

5. Verification checklist

• □ Re-check the original of Section D item 6 and confirm the currency is US dollars and the fee falls on the company.
• □ Check whether a new fee notice has appeared, including conversion to dinars or a switch to bank transfer.
• □ Re-check the history of ISO 9001 and 9002 and confirm that 9002 has been withdrawn, via the ISO standards catalogue.
• □ Verify on the ISO website the accreditation status and validity of the company’s ISO 13485:2016 certificate.
• □ Search the qualification clauses of KIMADIA and public hospital tenders of the past three years and tabulate how often each quality standard is required.
• □ Take evidence from companies that recently completed registration: which certificate types were required at acceptance and whether extra fees arose.
• □ Re-verify whether the official documents cited in this article have been replaced by subsequent instructions or resolutions (verification baseline date: October 29, 2026).

Regulatory information verified as of October 29, 2026.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support for the Iraqi market. Our team manages federal and Kurdistan registration applications, prepares reference-country dossiers, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com